NCT06089148

Brief Summary

Value of New Mammography Techniques in Comparison to Dynamic Contrast-Enhanced MRI of the Breast in the Detection and Diagnosis of Breast lesions

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
6.8 years until next milestone

First Submitted

Initial submission to the registry

October 2, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 18, 2023

Completed
Last Updated

October 18, 2023

Status Verified

October 1, 2023

Enrollment Period

1 year

First QC Date

October 2, 2023

Last Update Submit

October 16, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • sensitivity, specificity of'tomosynthesis and contrast enhanced mammography and MRI breast are measured in assessment of breast lesions and their pre-operative assessment of breast cancer

    diagnostic

    1year

Study Arms (1)

contrast enhanced mammography, tomosynthesis and MRI

CEDM and tomosynthesis versus MRI

Diagnostic Test: contrast enhanced digital mammography, tomosyntheis and MRI

Interventions

contrast enhanced mammography, tomosynthesis and MRI

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

FEMALE

You may qualify if:

  • Breast Imaging Reporting and Data System (BI-RADS) 3, 4, and 5 breast lesions.
  • Clinical indication for MRI breast imaging.

You may not qualify if:

  • \. Pregnancy or possible pregnancy. 2. History of allergy to an iodinated contrast agent. 3. Renal impairment. 4. Contraindication for MRI examination

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Diseases

Interventions

Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

TomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DR (lectureur)

Study Record Dates

First Submitted

October 2, 2023

First Posted

October 18, 2023

Study Start

June 1, 2015

Primary Completion

June 1, 2016

Study Completion

December 1, 2016

Last Updated

October 18, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will share

study protocol

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
1year
Access Criteria
http://www.medicine.cu.edu.eg/index.php/en/
More information

Available IPD Datasets

Study Protocol (Cairo unversity)Access